Form 4: Coeptis Therapeutics Holdings VP Acquires Stock Options

Christine Sheehy, VP of Compliance and Secretary at Coeptis Therapeutics Holdings, reports the acquisition of non-qualified stock options.

Summary

• On March 4, 2025, Christine Sheehy, VP of Compliance and Secretary at Coeptis Therapeutics Holdings, acquired 1,000 non-qualified stock options.
• These options were granted under the 2022 equity incentive plan.
• The exercise price is $10.56, equivalent to the company's stock price on the grant date.
• The options vest in equal quarterly installments over four years, with the final vesting date on December 31, 2028.
• The options expire ten years from the grant date.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider transaction, with no inherent positive or negative implications.

Positives

• The grant of stock options aligns the interests of the VP of Compliance and Secretary with the long-term performance of the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to incentivize and align management with shareholder interests.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment by aligning management's interests with those of shareholders.

Key Dates